|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-11-3
|
|
pubmed:abstractText |
A clinical study of the new 2-nitroimidazole nucleoside analogue doranidazole (PR-350) in combination with intraoperative radiotherapy is ongoing in Japan for localized unresectable pancreatic cancer. However, few data have been reported on the radiosensitivity and hypoxic fraction of human pancreatic cancers, and the efficacy of doranidazole against them. This study was undertaken to address these issues.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0167-8140
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
265-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10927148-Animals,
pubmed-meshheading:10927148-Cell Survival,
pubmed-meshheading:10927148-Humans,
pubmed-meshheading:10927148-Imidazoles,
pubmed-meshheading:10927148-Mice,
pubmed-meshheading:10927148-Mice, Inbred BALB C,
pubmed-meshheading:10927148-Pancreas,
pubmed-meshheading:10927148-Pancreatic Neoplasms,
pubmed-meshheading:10927148-Radiation Tolerance,
pubmed-meshheading:10927148-Radiation-Sensitizing Agents,
pubmed-meshheading:10927148-Reference Values,
pubmed-meshheading:10927148-Sensitivity and Specificity,
pubmed-meshheading:10927148-Tumor Cells, Cultured,
pubmed-meshheading:10927148-Whole-Body Irradiation
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
|
|
pubmed:affiliation |
Department of Oncology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
